By Scientia Professor Gregory John Dore

Journal articles

Martinello M; Schteinman A; Alavi M; Williams K; Dore GJ; Day R; Matthews GV, 2016, 'The impact of ribavirin plasma concentration on the efficacy of the interferon-sparing regimen, sofosbuvir and ribavirin', ANTIVIRAL THERAPY, 21, pp. 127 - 132, http://dx.doi.org/10.3851/IMP2984

Hezode C; Dore G; Pianko S; Pol S; Stuart K; Thompson A; Tse E; Bhore R; Jimenez-Exposito MJ, 2016, 'Daclatasvir plus Sofosbuvir plus Ribavirin for 12 or 16 Weeks in Treatment-Experienced Patients with HCV Genotype 3 Infection and Advanced Fibrosis or Cirrhosis', Journal of Hepatology, 64, pp. S753 - S754, http://dx.doi.org/10.1016/s0168-8278(16)01469-0

Grebely J; Flamm S; Zeuzem S; Hyland R; Chang P; Ding X; Yun C; Brainard D; McHutchison J; Forns X; Mangia A; Dore G, 2016, 'On-Treatment Illicit Drug Use Did Not Impact Treatment Outcome during Therapy with Ledipasvir-Sofosbuvi with or without Ribavirin in the Phase 3 ION-1 Study', Journal of Hepatology, 64, pp. S776 - S777, http://dx.doi.org/10.1016/s0168-8278(16)01514-2

Gastroenterology CAO; For The Study Of The Liver CA, 2016, 'Program and Abstracts from the Canadian Digestive Diseases Week™ 2016.', Can J Gastroenterol Hepatol, 2016, pp. 4792898, http://dx.doi.org/10.1155/2016/4792898

Grebely J; Dore GJ; Aspinall R; Rodriguez-Torres M; Fox R; Liu L; Ding X; McNally J; Osinusi A; Brainard D; Subramanian M; Sulkowski M; Feld J, 2016, 'SOF/VEL for 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy', Journal of Hepatology, 64, pp. S776 - S776, http://dx.doi.org/10.1016/s0168-8278(16)01513-0

Aghemo A; Dore GJ; Hatzakis A; Wedemeyer H; Razavi H, 2015, 'Estimating HCV disease burden - Volume 3 (editorial)', Journal of Viral Hepatitis, 22, pp. 1 - 3, http://dx.doi.org/10.1111/jvh.12473

Doyle JS; Deterding K; Grebely J; Wedemeyer H; Sacks-Davis R; Spelman T; Matthews G; Rice TM; Morris MD; McGovern BH; Kim AY; Bruneau J; Lloyd AR; Page K; Manns MP; Hellard ME; Dore GJ; Maher L, 2015, 'Response to treatment following recently acquired hepatitis C virus infection in a multicentre collaborative cohort', Journal of Viral Hepatitis, 22, pp. 1020 - 1032, http://dx.doi.org/10.1111/jvh.12429

Pianko S; Flamm SL; Shiffman ML; Kumar S; Strasser SI; Dore GJ; McNally J; Brainard DM; Han L; Doehle B; Mogalian E; McHutchison JG; Rabinovitz M; Towner WJ; Gane EJ; Stedman CAM; Rajender Reddy K; Roberts SK, 2015, 'Sofosbuvir plus velpatasvir combination therapy for treatment- Experienced patients with genotype 1 or 3 hepatitis c virus infection', Annals of Internal Medicine, 163, pp. 809 - 817, http://dx.doi.org/10.7326/M15-1014

Alavi M; Micallef M; Fortier E; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J, 2015, 'Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: The ETHOS study', Journal of Viral Hepatitis, 22, pp. 914 - 925, http://dx.doi.org/10.1111/jvh.12415

Sacks-Davis R; Grebely J; Dore GJ; Osburn W; Cox AL; Rice TM; Spelman T; Bruneau J; Prins M; Kim AY; Mcgovern BH; Shoukry NH; Schinkel J; Allen TM; Morris M; Hajarizadeh B; Maher L; Lloyd AR; Page K; Hellard M; Matthews G, 2015, 'Hepatitis c virus reinfection and spontaneous clearance of reinfection - The InC³ study', Journal of Infectious Diseases, 212, pp. 1407 - 1419, http://dx.doi.org/10.1093/infdis/jiv220

Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Strategies for achieving universal access to hepatitis C virus prevention and care for people who inject drugs', International Journal of Drug Policy, 26, pp. 1039 - 1040, http://dx.doi.org/10.1016/j.drugpo.2015.07.008

Fortier E; Alavi M; Micallef M; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Bruneau J; Grebely J, 2015, 'The effect of social functioning and living arrangement on treatment intent, specialist assessment and treatment uptake for hepatitis C virus infection among people with a history of injecting drug use: The ETHOS study', International Journal of Drug Policy, 26, pp. 1094 - 1102, http://dx.doi.org/10.1016/j.drugpo.2015.06.001

Keats J; Micallef M; Grebely J; Hazelwood S; Everingham H; Shrestha N; Jones T; Bath N; Treloar C; Dore GJ; Dunlop A; Haber P; Carolyn D; Gregory D; Tawil V; Krahn M; Loveday S; Thein HH, 2015, 'Assessment and delivery of treatment for hepatitis C virus infection in an opioid substitution treatment clinic with integrated peer-based support in Newcastle, Australia', International Journal of Drug Policy, 26, pp. 999 - 1006, http://dx.doi.org/10.1016/j.drugpo.2015.07.006

Larney S; Grebely J; Hickman M; De Angelis D; Dore GJ; Degenhardt L, 2015, 'Defining populations and injecting parameters among people who inject drugs: Implications for the assessment of hepatitis C treatment programs', International Journal of Drug Policy, 26, pp. 950 - 957, http://dx.doi.org/10.1016/j.drugpo.2015.07.010

Treloar C; Rance J; Bath N; Everingham H; Micallef M; Day C; Hazelwood S; Grebely J; Dore GJ, 2015, 'Evaluation of two community-controlled peer support services for assessment and treatment of hepatitis C virus infection in opioid substitution treatment clinics: The ETHOS study, Australia', International Journal of Drug Policy, 26, pp. 992 - 998, http://dx.doi.org/10.1016/j.drugpo.2015.01.005

Grebely J; Haire B; Taylor LE; Macneill P; Litwin AH; Swan T; Byrne J; Levin J; Bruggmann P; Dore GJ, 2015, 'Excluding people who use drugs or alcohol from access to hepatitis C treatments - Is this fair, given the available data?', Journal of Hepatology, 63, pp. 779 - 782, http://dx.doi.org/10.1016/j.jhep.2015.06.014

Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs', International Journal of Drug Policy, 26, pp. 893 - 898, http://dx.doi.org/10.1016/j.drugpo.2015.07.007

Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J; Marks P; Amin J; Doab A; Carroll T; Teutsch S; Li H; Oon A; Cameron B; Lloyd A; White P; Rawlinson W; Jacqueline Flynn ; Goy K; Nguyen O; von Bibra S; Ffrench R; McCaughan G; Madden A; Farrell G; Crofts N; Sievert W; Baker D; Jacka B; Pan Y; Shaw D; Sasadeusz J; Crawford D; Phung N; George J; Bloch M; Hughes B; Mollison L; Roberts S; Desmond P; Acraman B, 2015, 'Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C', International Journal of Drug Policy, 26, pp. 976 - 983, http://dx.doi.org/10.1016/j.drugpo.2015.05.003

Marshall AD; Micallef M; Erratt A; Telenta J; Treloar C; Everingham H; Jones SC; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop A; Jauncey M; Read P; Collie T; Dore GJ; Grebely J, 2015, 'Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study', International Journal of Drug Policy, 26, pp. 984 - 991, http://dx.doi.org/10.1016/j.drugpo.2015.07.002

Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2015, 'Recommendations for the management of hepatitis C virus infection among people who inject drugs', International Journal of Drug Policy, 26, pp. 1028 - 1038, http://dx.doi.org/10.1016/j.drugpo.2015.07.005

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; InC , 2015, 'Factors associated with hepatitis C virus RNA levels in early chronic infection: the InC³ study', Journal of Viral Hepatitis, 22, pp. 708 - 717, http://dx.doi.org/10.1111/jvh.12384

Martin NK; Vickerman P; Dore GJ; Hickman M, 2015, 'The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): The use of direct-acting antivirals as treatment for prevention', Current Opinion in HIV and AIDS, 10, pp. 374 - 380, http://dx.doi.org/10.1097/COH.0000000000000179

Barua S; Greenwald R; Grebely J; Dore GJ; Swan T; Taylor LE, 2015, 'Restrictions for medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States', Annals of Internal Medicine, 163, pp. 215 - 223, http://dx.doi.org/10.7326/M15-0406

Lamoury FMJ; Jacka B; Bartlett S; Bull RA; Wong A; Amin J; Schinkel J; Poon AF; Matthews GV; Grebely J; Dore GJ; Applegate TL, 2015, 'The influence of hepatitis C virus genetic region on phylogenetic clustering analysis', PLoS ONE, 10, pp. e0131437, http://dx.doi.org/10.1371/journal.pone.0131437

Eslam M; Hashem AM; Romero-Gomez M; Berg T; Dore GJ; Mangia A; Chan HLY; Irving WL; Sheridan D; Abate ML; Adams LA; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Nattermann J; Riordan S; Miele L; Kelaeng KS; Ampuero J; Ahlenstiel G; McLeod D; Powell E; Liddle C; Douglas MW; Booth DR; George J, 2015, 'FibroGENE: A gene-based model for staging liver fibrosis', Journal of Hepatology, 64, pp. 390 - 398, http://dx.doi.org/10.1016/j.jhep.2015.11.008

Dore GJ; Feld JJ, 2015, 'Hepatitis C virus therapeutic development: In pursuit of "perfectovir', Clinical Infectious Diseases, 60, pp. 1829 - 1836, http://dx.doi.org/10.1093/cid/civ197

Muir AJ; Poordad F; Lalezari J; Everson G; Dore GJ; Herring R; Sheikh A; Kwo P; Hézode C; Pockros PJ; Tran A; Yozviak J; Reau N; Ramji A; Stuart K; Thompson AJ; Vierling J; Freilich B; Cooper J; Ghesquiere W; Yang R; McPhee F; Hughes EA; Swenson ES; Yin PD, 2015, 'Daclatasvir in combination with asunaprevir and beclabuvir for hepatitis C virus genotype 1 infection with compensated cirrhosis', JAMA - Journal of the American Medical Association, 313, pp. 1736 - 1744, http://dx.doi.org/10.1001/jama.2015.3868

Cunningham EB; Applegate TL; Lloyd AR; Dore GJ; Grebely J, 2015, 'Mixed HCV infection and reinfection in people who inject drugs-impact on therapy', Nature Reviews Gastroenterology and Hepatology, 12, pp. 218 - 230, http://dx.doi.org/10.1038/nrgastro.2015.36

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Dore GJ; Grebely J, 2015, 'Patterns of hepatitis C Virus RNA levels during acute infection: The InC³ study', PLoS ONE, 10, pp. e0122232, http://dx.doi.org/10.1371/journal.pone.0122232

Lundgren J; Babiker A; Gordin F; Emery S; Fätkenheuer G; Molina JM; Wood R; Neaton JD; Agan BK; Alston-Smith B; Arenas-Pinto A; Arribas JR; Baker JV; Baxter J; Belloso WH; Brekke K; Brew B; Brobst SW; Burman W; Carey C; Clark R; Cooper DA; Davey RT; De La Rosa G; Denning ET; Dolan M; Dore G; Duprez D; Emanuel E; Grady C; Grund B; Hirschel B; Hoen B; Hudson F; Johnson MA; Kambili C; Klingman K; Kunisaki KM; Landay A; Ledergerber B; Lehrman SN; Martinez A; Meger S; Misar K; Mitsuyasu RT; Mocroft A; Munroe D; Norton M; Palmer RC; Pett SL; Phillips A; Pillay D; Porter D; Price RW; Proschan M; Rappoport C; Reiss P; Renjifo B; Robertson K; Rockstroh J; Rodriguez G; Rooney JF; Ross MJ; Schechter M; Schwarze S; Seekins D; Sharma S; Snowden W; Telenti A; Tryon J; van Wyk J; Vjecha MJ; Wright E; Cooper D, 2015, 'Why START? Reflections that led to the conduct of this large long-term strategic HIV trial', HIV Medicine, 16, pp. 1 - 9, http://dx.doi.org/10.1111/hiv.12227

Bradshaw D; Lamoury F; Catlett B; Applegate TL; McAllister J; Dore GJ; Matthews GV; Danta M, 2015, 'A comparison of seminal hepatitis C virus (HCV) RNA levels during recent and chronic HCV infection in HIV-infected and HIV-uninfected individuals', Journal of Infectious Diseases, 211, pp. 736 - 743, http://dx.doi.org/10.1093/infdis/jiu550

Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; De Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA, 2015, 'Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection', Gastroenterology, 148, pp. 355 - 366.e1, http://dx.doi.org/10.1053/j.gastro.2014.10.007

Spelman T; Morris MD; Zang G; Rice T; Page K; Maher L; Lloyd A; Grebely J; Dore GJ; Kim AY; Shoukry NH; Hellard M; Bruneau J; Cox AL; Lauer G; McGovern BH; Prins M; Hahn J; Shiboski S; Mirzazadeh A; Alavi M; Bouchard R; Evans J; Grady B; Aneja J; Sacks-Davis R; Teutsch S; White B; Wells B; Applegate T; Matthews G; Yeung B; Schinkel J; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J, 2015, 'A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugs', Journal of Epidemiology and Community Health, 69, pp. 745 - 752, http://dx.doi.org/10.1136/jech-2014-205224

Grebely J; Robaeys G; Bruggmann P; Aghemo A; Backmund M; Bruneau J; Byrne J; Dalgard O; Feld JJ; Hellard M; Hickman M; Kautz A; Litwin A; Lloyd AR; Mauss S; Prins M; Swan T; Schaefer M; Taylor LE; Dore GJ, 2015, 'Empfehlungen zur Hepatitis Versorgung bei Drogenkonsumierenden', International Journal of Drug Policy, 111, pp. 101670, http://dx.doi.org/10.1016/j.drugpo.2015.11.010

Wedemeyer H; Dore GJ; Ward JW, 2015, 'Estimates on HCV disease burden worldwide - Filling the gaps', Journal of Viral Hepatitis, 22, pp. 1 - 5, http://dx.doi.org/10.1111/jvh.12371

Lamoury FMJ; Bartlett S; Jacka B; Hajarizadeh B; Grebely J; Matthews GV; Dore GJ; Applegate TL, 2015, 'Interferon λ 3 and 4 genotyping using high-resolution melt curve analysis suitable for multiple clinical sample types', Journal of Molecular Diagnostics, 17, pp. 583 - 589, http://dx.doi.org/10.1016/j.jmoldx.2015.05.003

Eslam M; Hashem AM; Leung R; Romero-Gomez M; Berg T; Dore GJ; Chan HLK; Irving WL; Sheridan D; Abate ML; Adams LA; Mangia A; Weltman M; Bugianesi E; Spengler U; Shaker O; Fischer J; Mollison L; Cheng W; Powell E; Nattermann J; Riordan S; McLeod D; Armstrong NJ; Douglas MW; Liddle C; Booth DR; George J; Ahlenstiel G; Ampuero J; Bassendine M; Wong VWS; Rosso C; White R; Mezzabotta L; Suppiah V; Michalk M; Malik B; Matthews G; Applegate T; Grebely J; Fragomeli V; Jonsson JR; Santaro R, 2015, 'Interferon-λ rs12979860 genotype and liver fibrosis in viral and non-viral chronic liver disease', Nature Communications, 6, pp. 6422, http://dx.doi.org/10.1038/ncomms7422

Applegate TL; Gaudieri S; Plauzolles A; Chopra A; Grebely J; Lucas M; Hellard M; Luciani F; Dore GJ; Matthews GV, 2015, 'Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C', Antiviral Therapy, 20, pp. 199 - 208, http://dx.doi.org/10.3851/IMP2821

Bull RA; Leung P; Gaudieri S; Deshpande P; Cameron B; Walker M; Chopra A; Lloyd AR; Luciani F; Dolan K; Haber P; Rawlinson W; Treloar C; Dore G; Maher L, 2015, 'Transmitted/founder viruses rapidly escape from CD8⁺ T cell responses in acute hepatitis C virus infection', Journal of Virology, 89, pp. 5478 - 5490, http://dx.doi.org/10.1128/JVI.03717-14

Aspinall EJ; Hutchinson SJ; Janjua NZ; Grebely J; Yu A; Alavi M; Amin J; Goldberg DJ; Innes H; Law M; Walter SR; Krajden M; Dore GJ; Han A, 2015, 'Trends in mortality after diagnosis of hepatitis C virus infection: An international comparison and implications for monitoring the population impact of treatment', Journal of Hepatology, 62, pp. 269 - 277, http://dx.doi.org/10.1016/j.jhep.2014.09.001

Grebely J; Bruggmann P; Treloar C; Byrne J; Rhodes T; Dore GJ, 2015, 'Expanding access to prevention, care and treatment for hepatitis C virus infection among people who inject drugs', International Journal of Drug Policy, 26, pp. 893 - 898, http://dx.doi.org/10.1016/j.drugpo.2015.07.007

Sievert W; Razavi H; Thompson A; Zekry A; Dore GJ; Roberts SK, 2015, 'HCV‐infected patients need access now to new direct‐acting antiviral agents to avert liver‐related deaths', The Medical Journal of Australia, 202, pp. 479 - 479, http://dx.doi.org/10.5694/mja15.00165

Maher L; White B; Dore G; Lloyd A; Rawlinson W, 2015, 'Opioid substitution treatment protects against hepatitis C virus acquisition in people who inject drugs: The HITS-c study', Drug and Alcohol Dependence, 146, pp. e191 - e191, http://dx.doi.org/10.1016/j.drugalcdep.2014.09.435

Bretaña N; Boelen L; Bull R; Teutsch S; White P; Lloyd A; Luciani F; Bretana N; Dolan K; Rawlinson W; Dore G; Maher L, 2015, 'Transmission of Hepatitis C Virus among Prisoners, Australia, 2005–2012.', Emerging Infectious Diseases, 21, pp. 765 - 774, http://dx.doi.org/10.3201/eid2105.141832

Dore GJ; Knysz B; Luo Y; Janczewska E; Streinu-Cercel A; Caruntu FA; Motoc A; Mazur W; Shaw DR; Tornai I; Sasadeusz J; Skoien R; Sullivan D; Liu X; Podsadecki T, 2015, 'Tu1015 MALACHITE-II: Phase 3b Trial of Ombitasvir/Paritaprevir/R and Dasabuvir + Ribavirin or Telaprevir + Peginterferon/Ribavirin in Peginterferon/Ribavirin Treatment-Experienced Adults With HCV Genotype 1', Gastroenterology, 148, http://dx.doi.org/10.1016/s0016-5085(15)33704-5

Jacobson IM; Dore GJ; Wyles D; Lawitz E; Talal A; Ball G; Dumas EO; Feld JJ, 2015, 'Tu1024 Plasma Interferon-γ-Inducible Protein 10 (Ip-10) and Response to Interferon-Free Direct-Acting Antiviral Therapy in HCV Genotype 1-Infected Patients With and Without Cirrhosis', Gastroenterology, 148, http://dx.doi.org/10.1016/s0016-5085(15)33713-6

Grebely J; Dore GJ; Kim AY; Lloyd A; Shoukry NH; Prins M; Page K, 2014, 'Genetics of spontaneous clearance of hepatitis C virus infection: A complex topic with much to learn', Hepatology, 60, pp. 2127 - 2128, http://dx.doi.org/10.1002/hep.27163

Razavi H; Bruggmann P; Wedemeyer H; Dore G, 2014, 'Response to letter to the editor: Strategies to reduce HCV disease burden and HCV transmission need different models, as what works for end-stage liver disease may not work for HCV prevalence: A comment on the results presented in JVH Special Issue', Journal of Viral Hepatitis, 21, pp. e169 - e170, http://dx.doi.org/10.1111/jvh.12339

Hajarizadeh B; Grady B; Page K; Kim AY; McGovern BH; Cox AL; Rice TM; Sacks-Davis R; Bruneau J; Morris M; Amin J; Schinkel J; Applegate T; Maher L; Hellard M; Lloyd AR; Prins M; Geskus RB; Dore GJ; Grebely J; Lauer G; Shoukry NH; Hahn J; Shiboski S; Rice TM; Alavi M; Bouchard R; Aneja J; Teutsch S; White B; Wells B; Zang G; Matthews G; Marks P; Yeung B; Prince LE; Roy E; Bates A; Enriquez J; Chow S; McCredie L; Aitken C; Doyle J; Spelman T; Evans J, 2014, 'Interferon lambda 3 genotype predicts hepatitis C virus RNA levels in early acute infection among people who inject drugs: The InC³ Study', Journal of Clinical Virology, 61, pp. 430 - 434, http://dx.doi.org/10.1016/j.jcv.2014.08.027

Jacka B; Applegate T; Krajden M; Olmstead A; Harrigan PR; Marshall BDL; Debeck K; Milloy MJ; Lamoury F; Pybus OG; Lima VD; Magiorkinis G; Montoya V; Montaner J; Joy J; Woods C; Dobrer S; Dore GJ; Poon AFY; Grebely J, 2014, 'Phylogenetic clustering of hepatitis C virus among people who inject drugs in Vancouver, Canada', Hepatology, 60, pp. 1571 - 1580, http://dx.doi.org/10.1002/hep.27310

Back to profile page